In The News: SIWA Joins the fight against COVID-19

In The News
SIWA Therapeutics is excited to announce that we are doing our part in the global fight against COVID-19. Our humanized monoclonal antibody targets cells with an abnormally high level of glycolysis (known as the Warburg effect in cancer) and oxidative stress. This category includes, among other things, virally infected cells, including those infected by COVID-19. Read more below: http://biospace.com/article/chicago-biotech-company-testing-its-monoclonal-antibody-to-treat-covid-19/
Read More

In the News: SIWA Featured on Chicago Business Journal

In The News
Our founder and Chief Scientific Officer, Lewis Gruber recently spoke with Jim Dallke, Senior Editor of AmericanInno and contributor to American City Business Journals about SIWA Therapeutic’s groundbreaking work to defeat aging and age-related diseases. Read more here: https://www.bizjournals.com/chicago/news/2020/03/25/startup-siwa-therapeutics-aims-to-find-a-cure-for.html
Read More